Sanela Bilic

1st Term: 1/1/2015 - 6/30/2018
East Hanover, NJ

Degree(s):
PharmD, 2003, Drake University

Background:
Dr. Sanela Bilic has spent over 10 years in pharmaceutical industry working on antibody drug conjugates, immunotherapy and in general large proteins (including monoclonal antibodies, nanobodies, bispecifics). She has been with Novartis since 2004. Sanela is Director, Principal Fellow, Oncology Clinical Pharmacology and oversees the Clinical Pharmacology strategy of Antibody Drug Conjugates and Immunotherapy  at Novartis. Dr. Bilic is integral part of large molecule programs from early discovery to late stage development and provides strategic support for those. Prior to Novartis, Dr. Bilic completed a postdoctoral fellowship in Drug Development with focus on Clinical Pharmacology in Infectious diseases and Oncology at SUNY at Buffalo. Dr. Bilic has over 40 national and international posters, invited talks, and publications. Dr. Bilic obtained her MBA and Doctorate of Pharmacy (PharmD) from Drake University.

Click here to return to National Advisory Council